McKnight's Long-Term Care News21h
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
ENDPOINTS NEWS11h
David Bak­er, Demis Has­s­abis and John Jumper win chem­istry No­bel for com­pu­ta­tion­al pro­tein pre­dic­tion and de­sign
This year's prestigious Nobel Prize in Chemistry has been awarded to David Baker, the director of the Institute for Protein ...
ENDPOINTS NEWS5h
Ma­jor PBMs call for re­mov­ing three FTC com­mis­sion­ers from in­sulin law­suit
The three major PBMs being sued by the FTC have filed motions to disqualify the Democratic commissioners who would rule on ...
pharmaphorum22h
JPM: GSK announces $1.4bn deal to buy asthma biotech Aiolos
Things are, however, looking good for its latest launch, respiratory syncytial virus vaccine Arexvy, which GSK thinks can reach around $4 billion in annual sales. Zealand Pharma has suffered ...
precisionvaccinations22h
Precision Vaccinations
Eliminating fake vaccine news with pharmacist, nurse, and physician review. According to the Pan American Health Organization (PAHO) chikungunya data dashboard, the Federative Republic of Brazil has ...